A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma

Cisplatin-based concurrent chemoradiotherapy for patients with unresectable, locally advanced esophageal squamous cell carcinoma (ESCC) is associated with significant toxicities that are often intolerable. Prognosis for this subgroup of patients remains poor, and new therapeutic approaches are urgen...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Chuanhua, Lin, Li, Liu, Jianzhi, Liu, Rongrui, Chen, Yuling, Ge, Feijiao, Jia, Ru, Jin, Yang, Wang, Yan, Xu, Jianming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302991/
https://www.ncbi.nlm.nih.gov/pubmed/28087951
http://dx.doi.org/10.18632/oncotarget.9809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302991/
https://www.ncbi.nlm.nih.gov/pubmed/28087951
http://dx.doi.org/10.18632/oncotarget.9809

Ejemplares similares